SKB BIO-B (06990) announced that on March 10, 2026, the company entered into a 2026 Ancillary Market Management Services Framework Agreement with Kelun Jiaxun. Under this agreement, the Kelun Jiaxun Group will provide ancillary market management services to the company for the TROP2-targeting antibody-drug conjugate (ADC) sac-TMT (also known as SKB264/MK-2870), marketed under the brand name Jiatailai®. The Kelun Jiaxun Group offers comprehensive market management services, including but not limited to hospital listing information transmission, listing customer maintenance, market analysis services, market and competitor information collection, and academic conference support. The Kelun Jiaxun Group is well-versed in the business of promoting pharmaceutical products in China. It possesses specialized resources and experience, particularly in providing hospital listing information transmission services. By entering into the 2026 Ancillary Market Management Services Framework Agreement with the Kelun Jiaxun Group, the company will be able to leverage the group's existing resources to promote sac-TMT, thereby achieving listing targets more efficiently. Furthermore, since the Kelun Jiaxun Group began providing market management services for Cetuximab N01 Injection (formerly known as A140, brand name: Datailai®), the company has established a strong cooperative relationship with the group. The company believes that the Kelun Jiaxun Group possesses the necessary industry knowledge to effectively deliver the services outlined in the 2026 framework agreement. Engaging the Kelun Jiaxun Group also avoids the upfront costs associated with hiring a new service provider that has no prior collaboration history with the company.